CanSino Biologics Inc.

CanSino Biologics Inc. is a company dedicated to the development, manufacturing, and commercialization of vaccines across the People's Republic of China. Its current offerings encompass vaccines for recombinant novel coronavirus disease, specifically Convidecia and the Ad5-nCoV for inhalation, along with Ad5-EBOV, an Ebola virus vaccine. The company also provides MCV2 and MCV4, which are designed to prevent N. meningitides infections. CanSino's pipeline includes an infant DTcP vaccine and a DTcP Booster vaccine, both undergoing Phase I clinical trials, with the latter specifically aimed at enhancing protection against pertussis after primary immunization. A Tdcp vaccine for adolescents and adults, likewise focused on pertussis, is another product in development. Further candidates currently in Phase I trials are PBPV, a protein-based pneumococcal vaccine providing serotype-independent immunity; PCV13i, a pneumococcal conjugate vaccine; and a TB Booster intended for individuals previously vaccinated against tuberculosis with BCG. Beyond its clinical stage assets, the firm is also pursuing a variety of preclinical products. These encompass a DTcP-Hib Combo vaccine; CSB012, which targets adenovirus; CSB013 for the Zika virus; CSB015 for meningitis; CSB016 for shingles; and CSB107 for polio. Established in 2009, CanSino Biologics Inc. maintains its corporate headquarters in Tianjin, People's Republic of China.

CEO: Xuefeng Yu - https://www.cansinotech.com